ArticleOncoTargets and therapy2015

Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study.

Shukui Qin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.